ES2187568T3 - Vacuna viva para el tratamiento de enfermedades tumorales. - Google Patents
Vacuna viva para el tratamiento de enfermedades tumorales.Info
- Publication number
- ES2187568T3 ES2187568T3 ES95929003T ES95929003T ES2187568T3 ES 2187568 T3 ES2187568 T3 ES 2187568T3 ES 95929003 T ES95929003 T ES 95929003T ES 95929003 T ES95929003 T ES 95929003T ES 2187568 T3 ES2187568 T3 ES 2187568T3
- Authority
- ES
- Spain
- Prior art keywords
- vaccine
- cells
- gene
- against tumor
- tumor cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960005486 vaccine Drugs 0.000 title abstract 12
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 8
- 210000004027 cell Anatomy 0.000 abstract 5
- 210000004881 tumor cell Anatomy 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 2
- 238000010353 genetic engineering Methods 0.000 abstract 2
- 230000003308 immunostimulating effect Effects 0.000 abstract 2
- 230000002068 genetic effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5418—IL-7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
LA INVENCION TRATA DE LA OBTENCION Y UTILIZACION DE UNA VACUNA VIVA CONTRA CELULAS TUMORALES, QUE CONTIENE TRES GENES ADICIONALES OBTENIDOS POR INGENIERIA GENETICA: A) UN GEN QUE CODIFICA UNA PROTEINA DE LA SUPERFICIE CELULAR CON ACTIVIDAD INMUNOESTIMULANTE; B) UN GEN DE CITOQUINA, Y C) UN GEN DE TIMIDINA-QUINASA. LOS CAMPOS DE APLLICACION SON LA MEDICINA Y LA INGENIERIA GENETICA. LA INVENCION PROPONE UNA VACUNA CONTRA CELULAS TUMORALES, QUE TIENE SU EFECTIVIDAD PORQUE SE INDUCE UNA RESPUESTA ANTITUMORAL DE MANERA SINERGICA POR LA MULTIPLE TRANSFERENCIA DE GENES, QUE CODIFICAN LA ACTIVIDAD INMUNOESTIMULANTE. ESTO NOS LLEVA A UNA SEGURA REPULSION DE LAS CELULAS DE LA VACUNA Y NOS PERMITE INYECTAR COMO VACUNA CELULAS CAPACES DE MULTIPLICARSE. COMO MARCADORES ADICIONALES DE SEGURIDAD CONTIENEN LAS CELULAS DE LA VACUNA EL GEN DE LA TIMIDINA-QUINASA, QUE PERMITE LA MUERTE SELECTIVA DE LAS CELULAS DE LA VACUNA IN VIVO. LA EXPRESION DE LOS GENES CON ACTIVIDAD INMUNOESTIMULANTE MEJORA EL EFECTO DELA VACUNA EN COMPARACION CON VACUNAS YA CONOCIDAS CONTRA CELULAS TUMORALES, Y UNA VACUNA VIVA CONTRA CELULAS TUMORALES ES MAS EFECTIVA QUE UNA VACUNA COMPUESTA DE CELULAS CAPACES DE PROLIFERAR. LA VACUNA ES UTILIZABLE EN LA TERAPIA GENETICA EN PACIENTES CON TUMORES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4431401A DE4431401A1 (de) | 1994-08-24 | 1994-08-24 | Lebendvakzine gegen Tumorerkrankungen |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2187568T3 true ES2187568T3 (es) | 2003-06-16 |
Family
ID=6527332
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES95929003T Expired - Lifetime ES2187568T3 (es) | 1994-08-24 | 1995-08-18 | Vacuna viva para el tratamiento de enfermedades tumorales. |
Country Status (13)
Country | Link |
---|---|
US (1) | US6039941A (es) |
EP (1) | EP0777499B1 (es) |
JP (1) | JP2975117B2 (es) |
KR (1) | KR970705416A (es) |
AT (1) | ATE228016T1 (es) |
AU (1) | AU688101B2 (es) |
BR (1) | BR9508765A (es) |
CA (1) | CA2198234A1 (es) |
DE (3) | DE4431401A1 (es) |
DK (1) | DK0777499T3 (es) |
ES (1) | ES2187568T3 (es) |
PT (1) | PT777499E (es) |
WO (1) | WO1996005866A2 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7361332B2 (en) | 1995-03-17 | 2008-04-22 | The Regents Of The University Of California | Treating tumors using implants comprising combinations of allogeneic cells |
US5952221A (en) * | 1996-03-06 | 1999-09-14 | Avigen, Inc. | Adeno-associated virus vectors comprising a first and second nucleic acid sequence |
DE19626830A1 (de) * | 1996-07-04 | 1998-01-08 | Max Delbrueck Centrum | Konditionales Immortalisationsverfahren für humane Tumorzellen zur Herstellung einer Vakzine |
US6277368B1 (en) | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
KR20000049096A (ko) | 1996-10-11 | 2000-07-25 | 린다 에스. 스티븐슨 | 혼합 림프구와 조합된 종양세포를 사용하는 암 면역요법 |
AU785241B2 (en) * | 2000-05-17 | 2006-11-23 | Cancure Limited | Immune potentiating compositions |
AUPQ755300A0 (en) * | 2000-05-17 | 2000-06-08 | Monash University | Immune potentiating compositions |
PT2206517T (pt) * | 2002-07-03 | 2023-11-07 | Tasuku Honjo | Composições de imunopotenciação contendo anticorpos anti-pd-l1 |
GB0223696D0 (en) * | 2002-10-14 | 2002-11-20 | Ml Lab Plc | Improved immunotherapy |
JP2006096663A (ja) * | 2002-10-17 | 2006-04-13 | Sangaku Renkei Kiko Kyushu:Kk | 癌遺伝子ワクチン |
GB0227989D0 (en) * | 2002-12-02 | 2003-01-08 | Imp College Innovations Ltd | Chimaeric molecules |
AU2004275814A1 (en) * | 2003-09-26 | 2005-04-07 | University Of Miami | Tumor vaccine |
DK1699480T3 (da) | 2003-12-30 | 2011-10-10 | Mologen Ag | Allogent terapeutisk tumormiddel |
EA009325B1 (ru) | 2007-03-07 | 2007-12-28 | Петр Генриевич ЛОХОВ | Противоопухолевая вакцина, способ получения противоопухолевой вакцины и способ проведения противоопухолевой иммунотерапии |
EP2195650B1 (en) | 2007-09-12 | 2016-07-06 | Yeda Research And Development Company Ltd. | Methods of treating tumors in immune-privileged sites |
RU2407789C2 (ru) * | 2008-07-25 | 2010-12-27 | Виктор Владимирович Кешелава | Способ получения живой клеточной вакцины для профилактики рака молочных желез |
EA011421B1 (ru) * | 2008-08-26 | 2009-02-27 | Петр Генриевич ЛОХОВ | Способ получения противоопухолевой вакцины |
CA2740779A1 (en) | 2008-10-17 | 2010-04-22 | University Of Miami | Tumor vaccine |
CN111743884A (zh) * | 2019-03-26 | 2020-10-09 | 深圳先进技术研究院 | 苄丝肼或其衍生物的用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI91713C (fi) * | 1992-04-23 | 1994-08-10 | Axidental Oy | Uusia bioaktiivisia pinnotteita ja niiden valmistus ja käyttö |
ATE157261T1 (de) * | 1992-05-01 | 1997-09-15 | Us Health | Warte-effekt bei tumorzerstörender therapie |
WO1994004196A1 (en) * | 1992-08-14 | 1994-03-03 | Imperial Cancer Research Technology Limited | Tumour therapy |
-
1994
- 1994-08-24 DE DE4431401A patent/DE4431401A1/de not_active Withdrawn
-
1995
- 1995-08-18 DK DK95929003T patent/DK0777499T3/da active
- 1995-08-18 DE DE19580890T patent/DE19580890D2/de not_active Ceased
- 1995-08-18 EP EP95929003A patent/EP0777499B1/de not_active Expired - Lifetime
- 1995-08-18 PT PT95929003T patent/PT777499E/pt unknown
- 1995-08-18 ES ES95929003T patent/ES2187568T3/es not_active Expired - Lifetime
- 1995-08-18 CA CA002198234A patent/CA2198234A1/en not_active Abandoned
- 1995-08-18 BR BR9508765A patent/BR9508765A/pt unknown
- 1995-08-18 US US08/793,104 patent/US6039941A/en not_active Expired - Fee Related
- 1995-08-18 JP JP8507710A patent/JP2975117B2/ja not_active Expired - Fee Related
- 1995-08-18 AT AT95929003T patent/ATE228016T1/de not_active IP Right Cessation
- 1995-08-18 WO PCT/DE1995/001164 patent/WO1996005866A2/de active IP Right Grant
- 1995-08-18 KR KR1019970701175A patent/KR970705416A/ko not_active Application Discontinuation
- 1995-08-18 AU AU32531/95A patent/AU688101B2/en not_active Ceased
- 1995-08-18 DE DE59510466T patent/DE59510466D1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US6039941A (en) | 2000-03-21 |
BR9508765A (pt) | 1997-11-11 |
DE19580890D2 (de) | 1997-06-19 |
JPH10505339A (ja) | 1998-05-26 |
AU688101B2 (en) | 1998-03-05 |
AU3253195A (en) | 1996-03-14 |
EP0777499B1 (de) | 2002-11-20 |
MX9701384A (es) | 1998-03-31 |
EP0777499A1 (de) | 1997-06-11 |
DK0777499T3 (da) | 2003-03-17 |
KR970705416A (ko) | 1997-10-09 |
CA2198234A1 (en) | 1996-02-29 |
DE4431401A1 (de) | 1996-02-29 |
PT777499E (pt) | 2003-03-31 |
WO1996005866A3 (de) | 1996-04-11 |
DE59510466D1 (de) | 2003-01-02 |
WO1996005866A2 (de) | 1996-02-29 |
JP2975117B2 (ja) | 1999-11-10 |
ATE228016T1 (de) | 2002-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2187568T3 (es) | Vacuna viva para el tratamiento de enfermedades tumorales. | |
Weiner et al. | Genetic vaccines | |
Towne et al. | Optogenetic control of targeted peripheral axons in freely moving animals | |
PT1062321E (pt) | Utilizacoes para celulas estaminais mesenquimais humanas nao autologas | |
ES2185762T3 (es) | Vacunas contra la peste. | |
JP2014101379A (ja) | 遺伝子ベクターの局所施用によるワクチン接種 | |
ATE521629T1 (de) | Matrixmetalloproteinase-11-impfstoff | |
Cha et al. | Plasmid IL-12 electroporation in melanoma | |
CY1115407T1 (el) | Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων | |
WO2004087065A8 (en) | Compositions for induction of a therapeutic response | |
BRPI0418157A (pt) | terapêutica de tumores alogênicos | |
DE69434244D1 (de) | Verbesserte krebstherapie | |
NO932101L (no) | Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker | |
ES2114615T3 (es) | Nueva sonda para el diagnostico de tumores o la terapia de tumores. | |
BR0109928A (pt) | Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal | |
CY1111522T1 (el) | 84p2a9: ειδικη σε προστατη και ορχεις πρωτεϊνη που εκφραζεται σε υψηλο βαθμο στον προστατικο καρκινο | |
WO2003094828A3 (en) | Cancer vaccines and methods of using the same | |
ES2137172T3 (es) | Vacunas antitumorales que comprenden celulas transfectadas con il-6. | |
Sivanathan et al. | IL-17A–induced mesenchymal stem cells have promising therapeutic value for clinical translation | |
ES2171169T3 (es) | Uso de celulas tall-104 modificadas para tratar cancer y enfermedades virales. | |
DE602005021159D1 (de) | Bakteriophagen- und prophagen-proteine in der krebsgentherapie | |
UY31184A1 (es) | Composición vacunal homogénea para el tratamiento del cáncer y su método de obtención | |
Chiarella et al. | Intramuscular DNA vaccination protocols mediated by electric fields | |
EP1151756A4 (en) | USE OF POLYACRYLAMIDE GEL FOR PRODUCING A CAPSULE IN THE TISSUE OF A MAMMAL ORGANISM, METHOD FOR CULTURING CELLS AND METHOD FOR TREATING ONCOLOGICAL DISEASES AND DIABETES MELLITUS | |
Kharlamova et al. | A review of past and present hair cell regeneration techniques |